The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - Report of two cases

Psychiatria Danubina

Volumn 26, Issue 3, 2014, Pages 288-290

  Schmidt, Frank M ^a   Kirkby, Kenneth C ^b   Himmerich, Hubertus ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; ETANERCEPT; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; TIANEPTINE; TRANYLCYPROMINE; TRIMIPRAMINE; ANTIDEPRESSANT AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HUMAN; MIDDLE AGED; MONOTHERAPY; PSYCHOPHARMACOTHERAPY; TREATMENT RESISTANT DEPRESSION; BIPOLAR DISORDER; DRUG ANTAGONISM; MAJOR DEPRESSION; MALE; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907178349     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bhatia A, Kast RE: Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol 2007; 34:447-9.
2. Förstl H: Theory of mind. Neurobiologie und Psychologie sozialen Verhaltens. Springer-Verlag, Berlin, Heidelberg, New York, Hongkong, London, Mailand, Paris, Tokio, Wien, 2007.
3. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al.: Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008; 23:421-9.
4. Kahl KG, Greggersen W, Rudolf S, Stoeckelhuber BM, Bergmann-Koester CU, Dibbelt L, et al.: Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med 2006; 68:669-74.
5. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL: Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacol 2012; 62:419-26.
6. Kiank C, Zeden JP, Drude S, Domanska G, Fusch G, Otten W, et al.: Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One 2010; 5:e11825.
7. Krügel U, Fischer J, Radicke S, Sack U, Himmerich H: Antidepressant effects of TNF-α blockade in an animal model of depression. J Psychiatr Res 2013; 47:611-6.
8. Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H: Cytokines as biomarkers in depressive disorder: Current standing and prospects. Int Rev Psych 2013; 25:592-603.
9. Miyasaka N, Takeuchi T, Eguchi K: Guidelines for the proper use of etanercept in Japan. Mod Rheumatol 2006; 16:63e7.
10. Munzer A, Sack U, Mergl R, Schönherr J, Petersein C, Bartsch S, Kirkby KC, Bauer K, Himmerich H: Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins (Basel) 2013; 5:2227-40.
11. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS: The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009; 30:497-521.
12. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al.: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367:29-35.
13. Zhu CB, Blakely RD, Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmac 2006; 31:2121-31.